Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers.
Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on medical marijuana.
The survey was sent to 400 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.
Stories you may be interested in
After marijuana edibles helped dying Holocaust survivor battle Alzheimer’s, his family’s foundation pushes for more research
A Massachusetts family’s experience giving marijuana edibles to their dying patriarch is set to kick off a desperately needed investigation into how cannabis might treat some of the more troubling symptoms of Alzheimer’s disease, a condition that affects 5.7 million Americans. Read the full story here.
Read More
Former Detroit Lions players announce partnership with Harvard to study marijuana
Former Detroit Lions football players Calvin Johnson and Robert Sims are expanding their emerging cannabis enterprise into the field of medicine. The pair announced an agreement Thursday with the International Phytomedicines and Medical Cannabis Institute at Harvard University, which is researching the benefits of medical marijuana and looking at the best ways to deliver cannabis-based…
Read More 
Norfolk research company plans clinical trials using medical marijuana
Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions. Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer.…
Read More 
Updated Arfinn Med Scheduler
As your practice begins to grow, it’s important that your booking system is able to keep up. That’s why Arfinn Med has just released, in its newest update, the multi-view scheduling and booking platform. This allows you and/or your staff the ability to customize appointment types, hours of availability, display name, and confirmation emails for…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
New Feature: Text Message Treatment Updates
New to the Arfinn Med portal comes the ability to receive real time updates from patients via text messaging. This new addition will allow physicians to stay up to date on current patient efficacies as well as streamline the data collection process. Through the new text messaging function, physicians are able to send patients automated…
Read More